Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James G Ryall

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 19, 2007
Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopeniaJames G Ryall, Jonathan D Schertzer, Gordon S Lynch
Cell Stem Cell|December 7, 2015
Metabolic Reprogramming of Stem Cell EpigeneticsJames G Ryall, Tim Cliff, Stephen Dalton, et al.
Biogerontology|February 27, 2008
Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weaknessJames G Ryall, Jonathan D Schertzer, Gordon S Lynch
Cell Metabolism|May 21, 2020
A Metabolic Roadmap for Somatic Stem Cell FateC Hai Ly, Gordon S Lynch, James G Ryall
American Journal of Physiology. Endocrinology and Metabolism|April 20, 2006
Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic miceJonathan D Schertzer, James G Ryall, Gordon S Lynch
British Journal of Pharmacology|January 25, 2006
Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar dosesJames G Ryall, Martin N Sillence, Gordon S Lynch
Clinical and Experimental Pharmacology & Physiology|May 24, 2008
Anabolic agents for improving muscle regeneration and function after injuryGordon S Lynch, Jonathan D Schertzer, James G Ryall
Pharmacology & Therapeutics|January 30, 2007
Therapeutic approaches for muscle wasting disordersGordon S Lynch, Jonathan D Schertzer, James G Ryall
Genes & Development|June 12, 2013
The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophyValentina Proserpio, Raffaella Fittipaldi, James G Ryall, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|December 6, 2017
Therapeutic potential of heat shock protein induction for muscular dystrophy and other muscle wasting conditionsSavant S Thakur, Kristy Swiderski, James G Ryall, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 19, 2007
Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopeniaJames G Ryall, Jonathan D Schertzer, Gordon S Lynch
Cell Stem Cell|December 7, 2015
Metabolic Reprogramming of Stem Cell EpigeneticsJames G Ryall, Tim Cliff, Stephen Dalton, et al.
Biogerontology|February 27, 2008
Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weaknessJames G Ryall, Jonathan D Schertzer, Gordon S Lynch
Cell Metabolism|May 21, 2020
A Metabolic Roadmap for Somatic Stem Cell FateC Hai Ly, Gordon S Lynch, James G Ryall
American Journal of Physiology. Endocrinology and Metabolism|April 20, 2006
Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic miceJonathan D Schertzer, James G Ryall, Gordon S Lynch
British Journal of Pharmacology|January 25, 2006
Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar dosesJames G Ryall, Martin N Sillence, Gordon S Lynch
Clinical and Experimental Pharmacology & Physiology|May 24, 2008
Anabolic agents for improving muscle regeneration and function after injuryGordon S Lynch, Jonathan D Schertzer, James G Ryall
Pharmacology & Therapeutics|January 30, 2007
Therapeutic approaches for muscle wasting disordersGordon S Lynch, Jonathan D Schertzer, James G Ryall
Genes & Development|June 12, 2013
The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophyValentina Proserpio, Raffaella Fittipaldi, James G Ryall, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|December 6, 2017
Therapeutic potential of heat shock protein induction for muscular dystrophy and other muscle wasting conditionsSavant S Thakur, Kristy Swiderski, James G Ryall, et al.
Pageof 6